.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,972,906

« Back to Dashboard

Details for Patent: 5,972,906

Title: Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof
Abstract:A method for the treatment of mucous membrane trauma disease or condition for the relief of pain associated therewith comprising administering topically an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof.
Inventor(s): Asculai; Samuel Simon (Mississauga, CA), Russell; Alan Lawrence (Mississauga, CA), Falk; Rudolf Edgar (Mississauga, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Jul 19, 1995
Application Number:08/503,919
Claims:1. A method for the treatment of mucous membrane trauma and the immediate relief of pain associated therewith, the method comprising administering topically an effective dosage amount of 18-25 mg of a composition comprising a non-steroidal anti-inflammatory drug (N.S.A.I.D.) and a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof wherein said form of hyaluronic acid has a molecular weight less than 750,000 daltons and greater than 150,000 daltons.

2. The method of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate.

3. The method of claim 1 or 2 wherein the effective dosage amount of the composition contains 21/2% by weight of the form of hyaluronic acid and 3% by weight of the N.S.A.I.D.

4. The method of claim 1 or 2 wherein the effective dosage amount of the composition contains 21/2% by weight of the form of hyaluronic acid and 3% by weight of the N.S.A.I.D. wherein the N.S.A.I.D. is Diclofenac Sodium.

5. The method of claim 3 wherein the N.S.A.I.D. in the composition administered is Diclofenac Sodium.

6. A method for the immediate relief of pain associated with aphthous ulcers comprising administering an effective dosage amount of a composition comprising a non-steroidal anti-inflammatory drug (N.S.A.I.D.) and a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof, wherein the form of hyaluronic acid has a molecular weight less than 750,000 daltons and greater than 150,000 daltons.

7. The method of claim 6 wherein the form of hyaluronic acid is sodium hyaluronate.

8. The method of claim 6 or 7 wherein the effective dosage amount of the composition comprises an equivalent dosage amount of at least 18-25 mg. of a composition containing 21/2% by weight of the form of hyaluronic acid and 3% by weight of the N.S.A.I.D.

9. The method of claim 8 wherein the N.S.A.I.D. is Diclofenac Sodium.

10. A method for the immediate relief of pain associated with aphthous ulcers, the method comprising applying a dosage amount of a pharmaceutical composition to the aphthous ulcer, said composition comprising a form of hyaluronic acid selected from hyaluronic acid and pharmaceutically acceptable salts thereof, and a non-steroidal anti-inflammatory drug (NSAID), said amount of hyaluronic acid is at least about 0.375-0.625 mg. and said N.S.A.I.D. is at least about 0.45-0.75 mg. of N.S.A.I.D. and wherein said form of hyaluronic acid has a molecular weight less than 750,000 daltons and greater than 150,000 daltons.

11. The method of claim 10 wherein the form of hyaluronic acid is sodium hyaluronate and said NSAID is diclofenac sodium.

12. A dosage amount of a pharmaceutical composition comprising:

(i) an effective non-toxic dosage amount of a form of hyaluronic acid selected from hyaluronic acid and a pharmaceutically acceptable salt thereof, each having a molecular weight less than 750,000 daltons and greater than 150,000 daltons; and combinations thereof in the order of about 0.375-0.625 mg. per dosage application or more and

(ii) an effective non-toxic dosage amount of a non-steroidal anti-inflammatory drug (N.S.A.I.D.) in an amount effective to provide immediate relief of pain associated with aphthous ulcers in each dosage amount of said N.S.A.I.D. equivalent to at least about 0.45-0.75 mg. or more of Diclofenac sodium.

13. The method of claim 1 wherein the trauma is aphthous ulcers.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc